-
Product Insights
Dementia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Dementia- Global Clinical Trials Review, 2025" provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)- Global Clinical Trials Review, 2025" provides an overview of Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across...
-
Product Insights
High-Grade Glioma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “High-Grade Glioma- Global Clinical Trials Review, 2025" provides an overview of High-Grade Glioma Clinical trials scenario. This report provides top line data relating to the clinical trials on High-Grade Glioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Lennox-Gastaut Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome- Global Clinical Trials Review, 2025" provides an overview of Lennox-Gastaut Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Frozen Shoulder Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Frozen Shoulder Syndrome- Global Clinical Trials Review, 2025" provides an overview of Frozen Shoulder Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Frozen Shoulder Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also...
-
Sector Analysis
Hidradenitis Suppurativa (HS) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the HS market through 2034. Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with multifactorial etiology. Although its pathogenesis is not fully known, current evidence implicates genetic susceptibility, hormonal influences, environmental and lifestyle factors, microbial involvement, and immune dysregulation as central to disease initiation and propagation. These elements interact within a vulnerable follicular environment, culminating in the characteristic clinical features...
-
Sector Analysis
Immuno-oncology: Strategic Intelligence
This report includes coverage of immuno-oncology overview, trends, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field. The global market value for bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses increased from $10.4 billion in 2014 to $74 billion in 2024. This growth trajectory is expected to continue, with the total market reaching $186 billion by...
-
Sector Analysis
Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Key Highlights - Report deliverables include an Excel-based forecast model - Forecasts...
-
Sector Analysis
HER2-Negative Breast Cancer Epidemiology Analysis and Forecast to 2034
Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates from the milk ducts and invades the surrounding breast tissue (Cancer Research UK, 2023a). As it progresses, the cancer can metastasize to other parts of the body via the bloodstream and lymphatic system (American Cancer Society, 2022). According to the World Health Organization (WHO), breast cancer was the most common diagnosed cancer in women in 157...
-
Sector Analysis
Uveitis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the uveitis market through 2033. There will be an overall increase in the diagnosed prevalent cases of uveitis in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for uveitis involves the use of anti-inflammatory therapies. Significant clinical unmet needs remain in the uveitis market. The late-stage uveitis pipeline consists of six agents. The uveitis market in the 7MM was valued at...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.